APA (7th ed.) Citation

D, Q., A, N., D, S., M, M., C, M., V, S., . . . CL, B. (2023). Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study. Leukemia & lymphoma, 64(3), 738. https://doi.org/10.1080/10428194.2022.2164194

Chicago Style (17th ed.) Citation

D, Qualls, et al. "Molecularly Targeted Epigenetic Therapy with Mocetinostat in Relapsed and Refractory Non-Hodgkin Lymphoma with CREBBP or EP300 Mutations: An Open Label Phase II Study." Leukemia & Lymphoma 64, no. 3 (2023): 738. https://doi.org/10.1080/10428194.2022.2164194.

MLA (9th ed.) Citation

D, Qualls, et al. "Molecularly Targeted Epigenetic Therapy with Mocetinostat in Relapsed and Refractory Non-Hodgkin Lymphoma with CREBBP or EP300 Mutations: An Open Label Phase II Study." Leukemia & Lymphoma, vol. 64, no. 3, 2023, p. 738, https://doi.org/10.1080/10428194.2022.2164194.